Results 181 to 190 of about 5,972,941 (286)

Skin toxicity and effectiveness of first-line enfortumab vedotin plus pembrolizumab for urothelial carcinoma: a prospective multicenter real-world study in Japan. [PDF]

ESMO Real World Data Digit Oncol
Tamura K, Tsujino T, Taoka R, Kobayashi K, Miyake M, Ogawa K, Sasaki Y, Tatarano S, Katayama S, Kato M, Fukuhara H, Abe Y, Oda Y, Minato R, Shigehisa R, Maenosono R, Sugimoto M, Shiraishi K, Fujimoto K, Wada K, Furukawa J, Enokida H, Araki M, Uchida J, Inoue K, Inamoto T, West Japan Uro-oncology Collaboration Group.   +26 more
europepmc   +1 more source

Patients Undergoing Proximal Hamstring Repair Have High Rates of Return to Work and Favorable Outcomes: A Systematic Review

Arthroscopy, Sports Medicine, and Rehabilitation, EarlyView.
Purpose To evaluate return‐to‐work (RTW) rates and functional outcomes after surgical repair of proximal hamstring tendon avulsion injuries. Methods This systematic review followed Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines and was registered with the International Prospective Register of Systematic Reviews.
Arjan Bindra, Stephen M. Gillinov, Kevin G. Girardi, Kevin T. Lord, Jacob D. Kodra, Michael S. Lee, Louise Atadja, Mackenzie B. Norman, Jay Moran, Serkan Surucu, Andrew E. Jimenez   +10 more
wiley   +1 more source

Determinants of Difficult‐to‐Manage and Treatment‐Refractory Axial Spondyloarthritis: A Cross‐Sectional Analysis Within a Longitudinal Cohort

Arthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to estimate the prevalence of difficult‐to‐manage (D2M) and treatment‐refractory (TR) axial spondyloarthritis (axSpA) and to identify factors associated with D2M and TR disease in a longitudinal cohort. Methods We performed a cross‐sectional analysis on data from the Schroeder Arthritis Institute Spondylitis ...
Patricia Remalante‐Rayco, Laura Passalent, Tina Chim, Hannah Vijayan, Manal Alnasser, Zeynep Baskurt, Robert D. Inman, Nigil Haroon, Denis Poddubnyy   +8 more
wiley   +1 more source

Effectiveness of oral anticoagulants in precapillary pulmonary hypertension associated with systemic sclerosis: a EUSTAR cohort study. [PDF]

Rheumatology (Oxford)
Farina N, Bellando Randone S, Jenssen-Bjørkekjær H, Sanges S, Carreira P, Airò P, Guiducci S, Giuggioli D, Riemekasten G, Simeón Aznar CP, Bergmann C, Siegert E, Castellví I, Saketkoo LA, de Vries-Bouwstra J, Klemm P, Müller-Ladner U, Balbir-Gurman A, Smith V, Iannone F, Idolazzi L, Denton C, Rosato E, Maurer B, Allanore Y, Tanaka Y, Zanatta E, Truchetet ME, Kuwana M, Martin M, Cauli A, Solanki K, Del Galdo F, Gheorghiu AM, Anic B, Boleto G, Kumánovics G, Andréasson K, Rednic S, Chung LS, Oliveira S, Cadar M, Corrado A, de Souza Müller C, Hsu VM, Levy Y, Moroncini G, Henes J, Balanescu A, De Langhe E, Montecucco C, Sfikakis PP, Iudici M, Heitmann S, Vonk MC, Hoffmann-Vold AM, Distler O, Matucci Cerinic M, Bruni C.   +58 more
europepmc   +1 more source

Expert Perspectives: Toward Treat‐to‐Target Management in Adult Idiopathic Inflammatory Myopathies

Arthritis &Rheumatology, EarlyView.
Treat‐to‐target has transformed the management of several rheumatic diseases through predefined therapeutic goals, structured disease assessment, and timely treatment adjustment. Despite major advances in the understanding and treatment of idiopathic inflammatory myopathies (IIM), a formal treat‐to‐target framework for adult IIM has not yet been ...
Shiri Keret, Nantakarn Pongtarakulpanit, Rohit Aggarwal   +2 more
wiley   +1 more source

Efficacy and biomarker analysis for nivolumab in cancer of unknown primary: results from an investigator-initiated expanded access program. [PDF]

Int J Clin Oncol
Tanizaki J, Yonemori K, Takiguchi Y, Akiyoshi K, Komine K, Onozawa Y, Sato M, Hirata K, Onoe T, Ohkuma R, Horita Y, Minami H, Honda K, Suyama K, Ito A, Chiba Y, Watanabe H, Togashi Y, Sakai K, Nishio K, Nakagawa K, Hayashi H.   +21 more
europepmc   +1 more source

Initial treatment strategies and outcomes across haemodynamic thresholds and risk stratification in incident systemic sclerosis–associated pulmonary arterial hypertension: a EUSTAR analysis

Arthritis &Rheumatology, Accepted Article.
Objective Real‐world initial treatment strategies in SSc‐PAH remain incompletely described. We aimed to characterise these strategies across haemodynamic thresholds and risk strata and evaluate outcome associations. Methods We analysed treatment‐naïve SSc‐PAH patients in EUSTAR (2000–2021) fulfilling the 2022 haemodynamic definition.
Hilde Jenssen Bjørkekjær, Cosimo Bruni, Kaspar Broch, Cathrine Brunborg, Patricia E Carreira, Paolo Airò, Carmen Pilar Simeón‐Aznar, Marie‐Elise Truchetet, Alessandro Giollo, Alexandra Balbir‐Gurman, Mickael Martin, Christopher P Denton, Armando Gabrielli, Francesco Del Galdo, Madelon C. Vonk, Håvard Fretheim, Helle Bitter, Øyvind Midtvedt, Arne K. Andreassen, Sverre Høie, Yoshiya Tanaka, Gabriela Riemekasten, Ulf Müller‐Ladner, Marco Matucci‐Cerinic, Ivan Castellví, Elise Siegert, Eric Hachulla, Øyvind Molberg, Oliver Distler, Anna‐Maria Hoffmann‐Vold, on behalf of the EUSTAR collaborators   +30 more
wiley   +1 more source

Sustained Inhibition of Structural Damage Progression and Improvements in Disease Activity With Guselkumab in Biologic‐Naïve Participants with Active and Erosive Psoriatic Arthritis: Results Through Week 48 of the Phase 3b Randomized, Double‐Blind, Placebo‐Controlled APEX Study

Arthritis &Rheumatology, Accepted Article.
Objective In APEX, guselkumab, which binds to the IL‐23p19 subunit and CD64 on IL‐23‐producing cells, demonstrated significant joint efficacy and inhibition of structural damage progression in participants with active and erosive PsA through Week (W)24; W48 findings are reported herein. Methods The APEX modified full analysis set included 1020 biologic‐
Christopher T. Ritchlin, Philip J. Mease, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Karissa Lozenski, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde   +12 more
wiley   +1 more source

Improved outcomes with TKI maintenance after brexucabtagene autoleucel in Philadelphia chromosome ALL. [PDF]

Blood Adv
Othman T, Roloff GW, Miller K, Zhang A, Sutherland KC, Faramand R, Hill LC, Muhsen IN, Jeyakumar N, Ladha A, Sasine J, Lin C, Kopmar NE, Tsai SB, O'Connor TE, Hilal T, Solh MM, Guzowski C, Tan V, Majhail NS, Battiwalla M, Malik S, Mathews J, Shaughnessy P, Mountjoy L, Dykes KC, Logan AC, Schwartz M, Connor MP, Wang J, Vasu S, Kumaran M, Hoeg R, Tracy SI, Yalniz F, Yaghmour G, Pullarkat V, Cassaday RD, Leonard JT, Shah BD, Frey NV, Muffly LS, Aldoss I.   +42 more
europepmc   +1 more source

The development and validation of a new diagnostic sonographic enthesitis score for psoriatic arthritis: Diagnostic Ultrasound Enthesitis Tool (DUET)

Arthritis &Rheumatology, Accepted Article.
Objective The Diagnostic Ultrasound Enthesitis Tool (DUET) study aimed to develop and validate a new sonographic scoring system for enthesitis to aid PsA diagnosis. Methods We prospectively enrolled patients with early PsA, psoriasis without arthritis (PsO), and non‐inflammatory musculoskeletal symptoms as controls (CTL) from 17 centers. A standardized
Lihi Eder, Andre L. Ribeiro, Ricardo Acayaba de Toledo, Catherine Bakewell, Philippe Carron, Basant Elnady, Amir Haddad, Arthur Kavanaugh, Arnon Katz, Minna J. Kohler, Josefina Marin, Fahmeen Afgani, Nikolas Malliotis, Nam Nguyen, Adrien Nzeusseu, Ari Polachek, Ernesto Rodriguez, Marcos Rosemffet, Abha Singh, Maria S. Stoenoiu, Agnes Szentpetery, Ilaria Tinazzi, Janeth Yinh, Mu Yang, Dennis McGonagle, Richard Cook, Gurjit S. Kaeley, Sibel Z. Aydin   +27 more
wiley   +1 more source